J Bacteriol Virol.  2014 Jun;44(2):133-139. 10.4167/jbv.2014.44.2.133.

Host Immune Responses Against Type A Influenza Viruses

Affiliations
  • 1Department of Pharmacy, College of Pharmacy, Duksung Women's University, Seoul, Korea.
  • 2Department of Pharmacy, College of Pharmacy, Kyungpook National University, Daegu, Korea. hkang72@knu.ac.kr

Abstract

The influenza viruses are divided into 3 different types, A, B and C, all of them are known as human pathogens. However, only type A influenza viruses cause both epidemic and pandemic influenza. Typically, influenza virus infects a respiratory tract, targets a lung and causes an acute infectious disease. Influenza infection can be identified by a high fever, headache, body ache and extreme fatigue. Host immune system against Influenza infection consists of innate immune response and adaptive immune response. Innate immune responses include recognition of influenza viruses by alveolar macrophages and natural killer cells. Adaptive immune responses contain influenza virus specific antibody production by B cells and killing infected cells by cytotoxic T cells. Initially, influenza viruses are recognized by pattern recognition receptors (PRRs) on respiratory epithelial cells and alveolar macrophages, which can induce efficient anti-viral immune responses. Host immune responses play crucial roles in defense against influenza virus infection but sometimes these may contribute to immuno-pathology, which results in serious tissue damage. In this review, we went over the understanding of current literature on subtypes of influenza A viruses, important viral antigens and anti-viral immune mechanisms.

Keyword

Adaptive immunity; Hemagglutinin; Innate immunity; Neuraminidase; Type A influenza viruses

MeSH Terms

Adaptive Immunity
Antibody Formation
Antigens, Viral
B-Lymphocytes
Communicable Diseases
Epithelial Cells
Fatigue
Fever
Headache
Hemagglutinins
Homicide
Humans
Immune System
Immunity, Innate
Influenza A virus
Influenza, Human
Killer Cells, Natural
Lung
Macrophages, Alveolar
Neuraminidase
Orthomyxoviridae*
Pandemics
Receptors, Pattern Recognition
Respiratory System
T-Lymphocytes
Antigens, Viral
Hemagglutinins
Neuraminidase
Receptors, Pattern Recognition

Reference

1). Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A. 2012; 109:4269–74.
Article
2). WHO. fact sheet on influenza. 2009.
3). International Committee on Taxonomy of Viruses descriptions of: Orthomyxoviridae, Influenzavirus B and Influenzavirus C, Klenk. 2008.
4). Avian Influenza: Molecular Mechanisms of Pathogenesis and Host Range, Animal Viruses: Molecular Biology. Caister Academic Press;2008.
5). Hay A, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci. 2001; 356:1861–70.
Article
6). Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA. Influenza B virus in seals. Science. 2000; 288:1051–3.
Article
7). Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res. 2011; 162:19–30.
8). Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. Knipe DM, Howley PM, editors. Fields. Virology. 4th ed.Philadelphia USA: Lippincott Williams & Wilkins;;2001. p. 1487–531.
9). Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull. 2005; 28:399–408.
Article
10). Wilson JC, von Itzstein M. Recent strategies in the search for new anti-influenza therapies. Curr Drug Targets. 2003; 4:389–408.
Article
11). Potter CW. A history of influenza. J Appl Microbiol. 2001; 91:572–9.
Article
12). Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, et al. Influenza pandemics: past, present and future. J Formos Med Assoc. 2006; 105:1–6.
Article
13). Ramos I, Fernandez-Sesma A. Innate Immunity to H5N1 Influenza Viruses in Humans. Viruses. 2012; 4:3363–88.
Article
14). Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303:1526–9.
Article
15). Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A. 2004; 101:5598–603.
Article
16). Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010; 5:404–10.
Article
17). Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A. 2009; 106:7119–24.
Article
18). Kim HM, Lee YW, Lee KJ, Kim HS, Cho SW, van Rooijen N, et al. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J Virol. 2008; 82:4265–74.
Article
19). Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood MJ, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol. 2005; 79:14933–44.
Article
20). GeurtsvanKessel CH, Lambrecht BN. Division of labor between dendritic cell subsets of the lung. Mucosal Immunol. 2008; 1:442–50.
Article
21). Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001; 409:1055–60.
Article
22). Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, Burioni R. A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res. 2011; 92:15–26.
Article
23). Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol. 2001; 260:171–90.
Article
24). Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields. Virology. 5th ed.Lippincott Williams and Wilkins;2007.
25). Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol. 2011; 85:5027–35.
Article
26). Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, Kedzierska K. Immunity to seasonal and pandemic influenza A viruses. Microbes Infect. 2011; 13:489–501.
Article
27). Regner M, Pavlinovic L, Koskinen A, Young N, Trapani JA, Müllbacher A. Cutting edge: rapid and efficient in vivo cytotoxicity by cytotoxic T cells is independent of granzymes A and B. J Immunol. 2009; 183:37–40.
28). van Domselaar R, Bovenschen N. Cell death-independent functions of granzymes: hit viruses where it hurts. Rev Med Virol. 2011; 21:301–14.
Article
29). Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity. 1998; 8:683–91.
Article
30). Shimomura E, Suzuki F, Ishida N. Characterization of cells infiltrating the lungs of x-irradiated and nude mice after influenza virus infection. Microbiol Immunol. 1982; 26:129–38.
Article
31). Moskophidis D, Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med. 1998; 188:223–32.
Article
32). Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7:145–73.
Article
33). Graham MB, Braciale VL, Braciale TJ. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med. 1994; 180:1273–82.
Article
34). Surls J, Nazarov-Stoica C, Kehl M, Casares S, Brumeanu TD. Differential effect of CD4+Foxp3+ T-regulatory cells on the B and T helper cell responses to influenza virus vaccination. Vaccine. 2010; 28:7319–30.
Article
35). Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011; 11:119–30.
Article
36). La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol. 2007; 85:85–92.
Article
37). Lipatov AS, Andreansky S, Webby RJ, Hulse DJ, Rehg JE, Krauss S, et al. Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: the role of cytokines and B- and T-cell responses. J Gen Virol. 2005; 86:1121–30.
Article
38). Xu L, Yoon H, Zhao MQ, Liu J, Ramana CV, Enelow RI. Cutting edge: pulmonary immunopathology mediated by antigen-specific expression of TNF-alpha by antiviral CD8+ T cells. J Immunol. 2004; 173:721–5.
39). Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol. 2005; 79:6441–48.
Article
40). Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005; 6:135–39.
Article
41). Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol. 1997; 272:R621–30.
Article
42). Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol. 2000; 156:1951–9.
Article
43). de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12:1203–7.
Article
Full Text Links
  • JBV
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr